| Drug Name |
Ibandronate sodium |
| Drug ID |
BADD_D01116 |
| Description |
Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid].[A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.[A203138]
Ibandronate was granted FDA approval on 16 May 2003.[L13805] |
| Indications and Usage |
For the treatment and prevention of osteoporosis in postmenopausal women.[L13805,L13808] |
| Marketing Status |
approved; investigational |
| ATC Code |
M05BA06 |
| DrugBank ID |
DB00710
|
| KEGG ID |
D04486
|
| MeSH ID |
D000077557
|
| PubChem ID |
23670359
|
| TTD Drug ID |
D08SJZ
|
| NDC Product Code |
14593-853; 65862-237; 47781-103; 55111-575; 60429-643; 60505-4003; 51224-008; 65862-270; 60505-2795; 60505-6097; 33342-150; 55150-191; 67457-524; 69452-378; 63850-4355; 0004-0186 |
| UNII |
J12U072QL0
|
| Synonyms |
Ibandronic Acid | Ibandronate | 1-Hydroxy-3-(methylpentylamino)propylidenebisphosphonate | (1-Hydroxy-3-(methylpentylamino)propylidene)bisphosphonate | Ibandronate Sodium Anhydrous | Boniva | Bonviva | Ibandronate Sodium | Ibandronic Acid, Sodium Salt, Monohydrate | RPR 102289A | RPR-102289A | RPR102289A | Bondronat | BM 21.0955 | BM 210955 | BM-21.0955 | BM21.0955 | BM-210955 | BM210955 |
